Premium
Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedema
Author(s) -
Kreuz Wolfhart,
Rusicke Eva,
MartinezSaguer Inmaculada,
AygörenPürsün Emel,
Heller Christine,
Klingebiel Thomas
Publication year - 2012
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2011.03240.x
Subject(s) - hereditary angioedema , medicine , dosing , laryngeal edema , edema , intravenous therapy , angioedema , retrospective cohort study , pediatrics , anesthesia , surgery , dermatology
BACKGROUND: C1‐esterase inhibitor (C1‐INH) replacement therapy is the treatment of choice for acute edema attacks in patients with hereditary angioedema (HAE). STUDY DESIGN AND METHODS: Our retrospective, observational study assessed the efficacy and safety of home therapy with a human plasma‐derived C1‐INH concentrate (pC1‐INH) in 20 pediatric patients with HAE who had previously been treated with physician‐based therapy. While on home therapy, 15 patients received on‐demand treatment and five received individual replacement treatment (IRT). RESULTS: The switch to home therapy did not involve a significant increase in the dose of pC1‐INH administered, but there was a significant increase in dosing frequency. Although only two patients were affected, the frequency of laryngeal attacks appeared to decrease on home therapy. All attacks, including laryngeal edema, were treated successfully during home therapy with pC1‐INH. The mean annual number of days hospitalized was reduced from 3.8 during physician‐based therapy to 0.11 during home therapy. No side effects or injection site complications were reported. The median time from onset of attack to administration of pC1‐INH was reduced from 67.5 minutes during physician‐based therapy to 15 minutes after switching to home therapy. The corresponding median time to initial symptom relief for all types of attack was reduced from 60 to 40 minutes. CONCLUSION: As in adults, home therapy with pC1‐INH is effective and safe in the treatment of HAE attacks in pediatric patients; a larger, randomized study should ideally confirm our findings before this approach can be considered the standard of care for pediatric patients.